Inmune Bio

INMBNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$59.948 M

$2.16 -5.68%

Close of 22 Sept 2026

Revenue

$50.0K

#3608 by revenue

Earnings

-$46.0M

Loss-making

Shares outstanding

27,753,789

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#122Eloxx PharmaceuticalsELOX$67.5M
#123MiNK TherapeuticsINKT$61.8M
#124Inmune BioINMB$59.9M
#125ExozymesEXOZ$57.5M
#126LeonaBioLONA$57.0M

What if Inmune Bio were worth as much as…

Open the what-if tool →

Gold $30.2T

$1,089,364

Per share 504,335× higher

Bitcoin $1.74T

$62,753.78

Per share 29,053× higher

Nvidia $5.52T

$198,739.24

Per share 92,009× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Inmune Bio are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.